SCHEMBL1160587

SCHEMBL1160587

CCOC(=O)c1cc2c(n1Cc1ccc(C)cc1)C(=O)CCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 1/20 0.54
NOD1 Q9Y239 1/20 0.54
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 2/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 9/20 0.44
TDP1 Q9NUW8 4/20 0.44
NPSR1 Q6W5P4 3/20 0.44
MAPK1 P28482 1/20 0.44
LMNA P02545 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
GAA P10253 2/20 0.44
POLB P06746 2/20 0.43
HTT P42858 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 4/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31681757 0.99 NOD2 (0.55) NOD2NOD1ALDH1A1KDM4EHSD17B10
SCHEMBL31681753 0.92 MAPT (0.54) NOD2NOD1ALDH1A1KDM4EHSD17B10
SCHEMBL23854160 0.91 NOD2 (0.44) NOD2NOD1ALDH1A1KDM4EHSD17B10
SCHEMBL23852569 0.91 MAPT (0.53) NOD2NOD1ALDH1A1KDM4ETP53
SCHEMBL23853369 0.91 NOD2 (0.44) NOD2NOD1ALDH1A1KDM4EHSD17B10
SCHEMBL6115173 0.91 TSHR (0.52) NOD2NOD1ALDH1A1KDM4EHSD17B10
SCHEMBL18250041 0.91 MAPT (0.52) NOD2NOD1ALDH1A1KDM4EHSD17B10
SCHEMBL6115574 0.90 MEN1 (0.45) NOD2NOD1ALDH1A1KDM4EHSD17B10
SCHEMBL23853955 0.89 NOD2 (0.42) NOD2NOD1ALDH1A1KDM4EHSD17B10
SCHEMBL31681758 0.89 NOD2 (0.42) NOD2NOD1ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410164-B2 Heterocyclic compounds and medical use thereof FONDAZIONE TELETHON (IT) 2025-09-09 US disclosed
US-20120129884-A1 PHOTOCHEMOTHERAPEUTIC HETEROCYCLIC AGENTS HAVING ANTIPROLIFERATIVE AND ANTINEOPLASTIC ACTIVITY UNIVERSITA DEGLI STUDI DI PADOVA (IT) 2012-05-24 US disclosed
WO-2011013159-A1 PHOTOCHEMOTHERAPEUTIC HETEROCYCLIC AGENTS HAVING ANTIPROLIFERATIVE AND ANTINEOPLASTIC ACTIVITY UNIVERSITÀ DEGLI STUDI DI PADOVA (IT) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410164-B2 Heterocyclic compounds and medical use thereof NPPA, NPR1, CYC1 NOD2 183/4885NOD1 400/4885ALDH1A1 2994/4885
US-20120129884-A1 PHOTOCHEMOTHERAPEUTIC HETEROCYCLIC AGENTS HAVING ANTIPROLIFERATIVE AND ANTINEOPLASTIC ACTIVITY PCNA, ERCC4, UBQLN2 NOD2 2895/4885NOD1 4016/4885ALDH1A1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.